Trial Profile
Efficacy and safety of once daily insulin IDeg/Asp switching from basal insulin in inadequately controlled Japanese patients with type 2 diabetes: A 4-week, randomized, open-label, treat-to-target trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2018
Price :
$35
*
At a glance
- Drugs Insulin degludec/insulin aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 09 Jan 2018 New trial record
- 08 Dec 2017 Results presented at the 2017 Congress of the International Diabetes Federation